While well-developed in cancers, precision medicine's readiness for prime time beyond oncology varies markedly from disease to disease. But reimbursement remains a significant hurdle.
In a phone interview, Propeller Health CEO David Van Sickle and CTO Greg Tracy discussed how their digital therapeutics company has evolved since its founding in 2010.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
In an earnings call last week CVS Health CEO Larry Merlo outlined some of the ways that the company is moving forward on plans to reduce medical costs after its $69 billion purchase of Aetna.
The goal is to expand its connected device capabilities beyond asthma and COPD inhalers to include other diseases and drug delivery devices.
It is the latest in a series of developments for diagnostics business Owlstone Medical, which recently brought its breath biopsy kits to market.
The move is designed to help the New Zealand device company accelerate distribution of its sensor following the opening of a U.S. office in San Mateo, California, earlier this year.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
New Zealand remote monitoring company for respiratory conditions, Adherium, has opened up offices in San Mateo to pave the way for its expansion to the U.S. market.
Express Scripts members who used Propeller's inhaler tracking tools had a significant improvement in adherence to their asthma controller medication, according to the pharmacy benefit manager.
The FDA has cleared the third iteration of Adherium's adherence monitoring tool, this time for the AstraZeneca Symbicort inhaler for people with asthma and COPD.
Of the five major respiratory inhaler companies in the U.S., Propeller Health has now signed three. The latest addition, Novartis, gives Propeller an edge as it works to claim market share in the 'smart inhaler' sector projected to be worth $854 million per year by 2025.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Smart Respiratory Products is planning to make available its digital peak flow meter next year to help asthma patients to stay on top of their condition.
The deal adds spirometers and spirometry data to Propeller's platform, expanding the size of the patient population the company targets.
Rising rates of allergies worldwide will cause the global market for allergy diagnostics to nearly triple from $1.3 billion in 2015 to $3.8 billion in 2024, says a new report.
Spirometrix wants to see nearly 20 percent of pulmonologists and allergists using the Fenom Pro sensor by 2020.
Although a report from the London-based Asthma UK supports the progress of connected devices to manage asthma, it was critical of "piecemeal" solutions that have failed to reduce complexities and guesswork from managing an episodic condition with multiple triggers.